Ipsen reports sales and profit growth for half year 2020

30 July 2020

French drugmaker Ipsen (Euronext: IPN) today announced financial results for the first half of 2020, with the firm’s shares gaining 12.1% to 82.20 euros by early afternoon. Sales were up 3.1% (as reported and constant currency) at 1.27 billion euros ($1.49 billion).

Sales were driven by Specialty Care growth of 5.9%, led by Somatuline (lanreotide) (up 16.4%). Consumer Healthcare sales were down 21.1%. Second-quarter 2020 group sales decreased by 2.2% adversely impacted by COVID-19.

Core consolidate net profit was 297 million euros and fully diluted core earnings per share (EPS) were 3.55 euros (up 5.0%). Consolidated net profit came in at 223 million euros and fully diluted IFRS EPS of 2.66 euros (up 1.0%).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK